野村发表研究报告指出,翰森制药(03692.HK) 预计2026财年收入与盈利均录得10%增长。该行预期翰森2025年下半年收入将按年增长27%至73亿元人民币(下同),略高于市场共识预测,包括药品销售按年增长17%至66亿元,以及确认7.43亿元的合作收入。该行预测已计入肿瘤及抗感染药品销售持续增长,以及与再生元制药的合作。野村预计翰森制药2025年下半年利润率将有所提升,毛利率91.6%(按年...
Source Link野村发表研究报告指出,翰森制药(03692.HK) 预计2026财年收入与盈利均录得10%增长。该行预期翰森2025年下半年收入将按年增长27%至73亿元人民币(下同),略高于市场共识预测,包括药品销售按年增长17%至66亿元,以及确认7.43亿元的合作收入。该行预测已计入肿瘤及抗感染药品销售持续增长,以及与再生元制药的合作。野村预计翰森制药2025年下半年利润率将有所提升,毛利率91.6%(按年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.